1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Spondyloarthritis (Spondyloarthropathy) Global Clinical Trials Review, H2, 2015

Spondyloarthritis (Spondyloarthropathy) Global Clinical Trials Review, H2, 2015

Summary

GlobalData's clinical trial report, “Spondyloarthritis (Spondyloarthropathy) Global Clinical Trials Review, H2, 2015" provides an overview of Spondyloarthritis (Spondyloarthropathy) clinical trials scenario. This report provides top line data relating to the clinical trials on Spondyloarthritis (Spondyloarthropathy). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Spondyloarthritis (Spondyloarthropathy) Global Clinical Trials Review, H2, 2015
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Report Guidance 4
Clinical Trials by Region 5
Clinical Trials and Average Enrollment by Country 6
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Clinical Trials by G7 Countries: Proportion of Spondyloarthritis (Spondyloarthropathy) to Musculoskeletal Clinical Trials 12
Clinical Trials by Phase in G7 Countries 14
Clinical Trials in G7 Countries by Trial Status 15
Clinical Trials by E7 Countries: Proportion of Spondyloarthritis (Spondyloarthropathy) to Musculoskeletal Clinical Trials 16
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Spondyloarthritis (Spondyloarthropathy) Therapeutics Clinical Trials 27
Prominent Drugs 29
Clinical Trial Profile Snapshots 30
Appendix 50
Abbreviations 50
Definitions 50
Research Methodology 51
Secondary Research 51
About GlobalData 52
Contact Us 52
Disclaimer 52
Source 53

List of Tables
Spondyloarthritis (Spondyloarthropathy) Therapeutics, Global, Clinical Trials by Region, 2015* 5
Spondyloarthritis (Spondyloarthropathy) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 7
Spondyloarthritis (Spondyloarthropathy) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 8
Spondyloarthritis (Spondyloarthropathy) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2015* 9
Spondyloarthritis (Spondyloarthropathy) Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 10
Spondyloarthritis (Spondyloarthropathy) Therapeutics Clinical Trials, North America, Top Countries, 2015* 11
Proportion of Spondyloarthritis (Spondyloarthropathy) to Musculoskeletal Clinical Trials, G7 Countries (%), 2015* 13
Spondyloarthritis (Spondyloarthropathy) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 14
Spondyloarthritis (Spondyloarthropathy) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 15
Proportion of Spondyloarthritis (Spondyloarthropathy) to Musculoskeletal Clinical Trials, E7 Countries (%), 2015* 17
Spondyloarthritis (Spondyloarthropathy) Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 18
Spondyloarthritis (Spondyloarthropathy) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 19
Spondyloarthritis (Spondyloarthropathy) Therapeutics, Global, Clinical Trials by Phase, 2015* 20
Spondyloarthritis (Spondyloarthropathy) Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 21
Spondyloarthritis (Spondyloarthropathy) Therapeutics, Global, Clinical Trials by Trial Status, 2015* 22
Spondyloarthritis (Spondyloarthropathy) Therapeutics Clinical Trials, Global, by End Point Status, 2015* 23
Spondyloarthritis (Spondyloarthropathy) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 24
Spondyloarthritis (Spondyloarthropathy) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 25
Spondyloarthritis (Spondyloarthropathy) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 26
Spondyloarthritis (Spondyloarthropathy) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 28
Spondyloarthritis (Spondyloarthropathy) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 29

List of Figures
Spondyloarthritis (Spondyloarthropathy) Therapeutics, Global, Clinical Trials by Region (%), 2015* 5
Spondyloarthritis (Spondyloarthropathy) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 6
Spondyloarthritis (Spondyloarthropathy) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 8
Spondyloarthritis (Spondyloarthropathy) Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2015* 9
Spondyloarthritis (Spondyloarthropathy) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 10
Spondyloarthritis (Spondyloarthropathy) Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 11
Proportion of Spondyloarthritis (Spondyloarthropathy) to Musculoskeletal Clinical Trials, G7 Countries (%), 2015* 12
Spondyloarthritis (Spondyloarthropathy) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 14
Spondyloarthritis (Spondyloarthropathy) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 15
Proportion of Spondyloarthritis (Spondyloarthropathy) to Musculoskeletal Clinical Trials, E7 Countries (%), 2015* 16
Spondyloarthritis (Spondyloarthropathy) Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 18
Spondyloarthritis (Spondyloarthropathy) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 19
Spondyloarthritis (Spondyloarthropathy) Therapeutics, Global, Clinical Trials by Phase (%), 2015* 20
Spondyloarthritis (Spondyloarthropathy) Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 21
Spondyloarthritis (Spondyloarthropathy) Therapeutics, Global, Clinical Trials by Trial Status, 2015* 22
Spondyloarthritis (Spondyloarthropathy) Therapeutics Clinical Trials, Global, by End Point Status, 2015* 23
Spondyloarthritis (Spondyloarthropathy) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 24
Spondyloarthritis (Spondyloarthropathy) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 25
Spondyloarthritis (Spondyloarthropathy) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 26
Spondyloarthritis (Spondyloarthropathy) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 27
Spondyloarthritis (Spondyloarthropathy) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 29
GlobalData Methodology 51

Companies Mentioned
Merck and Co., Inc.
AbbVie Inc.
Johnson and Johnson
Vianex S.A.
Sint Maartenskliniek
Laboratoires Stella SA
Ion Beam Applications S.A.
Given Imaging Ltd.
Abbott Laboratories

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.